Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
48.69
+1.19 (+2.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today
July 30, 2021
Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate.
Via
InvestorPlace
Why CRISPR Therapeutics' Stock Is Trading Higher Today
July 30, 2021
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading higher Friday morning after the company announced second-quarter financial results that showed significant improvement year over...
Via
Benzinga
Why CRISPR Therapeutics' Stock Is Trading Higher Today
July 29, 2021
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year. 'We expect...
Via
Benzinga
Crispr Therapeutics Represents the Best of Emerging Biotechnology
July 26, 2021
CRSP stock may end up being a pioneer, or it may fizzle. The timeline until we know is typical of biotech stocks.
Via
InvestorPlace
Is CRISPR Therapeutics a Millionaire-Maker Stock?
July 24, 2021
It's already well on its way, but the road ahead will be long.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
3 Things About CRISPR Therapeutics That Smart Investors Know
July 23, 2021
The company is on track to be the first to market with a gene-editing therapy for blood disorders.
Via
The Motley Fool
Crispr Therapeutics Has Bullish DNA
July 22, 2021
Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning.
Via
InvestorPlace
Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns?
July 19, 2021
Ethical concerns will likely dog CRISPR Therapeutics stock, especially with the present social awakening.
Via
InvestorPlace
Topics
Economy
Exposures
COVID-19
Economy
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
July 16, 2021
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
Via
The Motley Fool
Cramer Gives His Opinion On Wynn Resorts, Advanced Micro Devices And More
July 14, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Blackstone Group Inc (NYSE: BX) very much. He keeps buying Wynn Resorts, Limited (NASDAQ: WYNN) for...
Via
Benzinga
How Investors Can Own A Piece Of Tesla, Shopify, CRISPR Therapeutics
July 12, 2021
Investing in the ARK Innovation ETF (NYSE:ARKK) is the ...
Via
Benzinga
WHO Issues Framework For Governance For Gene Editing Technologies
July 12, 2021
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...
Via
Benzinga
A Comprehensive Guide To Genomic ETFs
July 11, 2021
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...
Via
Talk Markets
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
July 11, 2021
There are still some key unanswered questions for the biotech's promising gene-editing therapy.
Via
The Motley Fool
Mid-Cap Biotech Picks: Seasonal Rally Underway
July 03, 2021
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable.
Via
Talk Markets
Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus
July 02, 2021
The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped.
Via
Investor's Business Daily
Topics
Initial Public Offering
Stocks
Exposures
Fossil Fuels
Securities Market
US Equities
Here's What Drove Gene Editing Stocks Higher This Week
July 02, 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
Via
The Motley Fool
'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
June 30, 2021
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...
Via
Benzinga
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
June 30, 2021
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.
Via
InvestorPlace
Why Gene Editing Stocks Are Trading Higher Again Today
June 30, 2021
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...
Via
Benzinga
60 Biggest Movers From Yesterday
June 29, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...
Via
Benzinga
44 Stocks Moving In Monday's Mid-Day Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...
Via
Benzinga
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
June 28, 2021
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.
Via
Investor's Business Daily
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
June 28, 2021
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics.
Via
InvestorPlace
24 Stocks Moving in Monday's Pre-Market Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...
Via
Benzinga
Crispr Therapeutics Stock Sees Improved Relative Strength Rating
June 25, 2021
Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74.
Via
Investor's Business Daily
Gold Stocks On Sale
June 20, 2021
In this video, we discuss our top stocks of the week, how gold is on sale, and how some market signals have been particularly troubling and misread.
Via
Talk Markets
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
June 18, 2021
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap...
Via
Talk Markets
Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More
June 17, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said Martin Marietta Materials, Inc. (NYSE: MLM) is a well-run company. He likes the stock because it doesn't...
Via
Benzinga
CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases
June 15, 2021
CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a...
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.